|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-7-14
|
|
pubmed:abstractText |
Type 2 diabetes mellitus (T2DM) patients have a variable response profile to the P2Y(12) receptor antagonist clopidogrel. P2Y(12) receptor signalling promotes platelet procoagulant activity. The aim of this study was to determine if T2DM patients with suboptimal clopidogrel response have greater platelet procoagulant activity compared with optimal responders and evaluate if this can be modulated by enhancing P2Y(12) receptor inhibition.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1879-2472
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
124
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
318-22
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19012950-Blood Coagulation Factors,
pubmed-meshheading:19012950-Diabetes Mellitus, Type 2,
pubmed-meshheading:19012950-Female,
pubmed-meshheading:19012950-Humans,
pubmed-meshheading:19012950-Male,
pubmed-meshheading:19012950-Middle Aged,
pubmed-meshheading:19012950-Platelet Activation,
pubmed-meshheading:19012950-Platelet Aggregation Inhibitors,
pubmed-meshheading:19012950-Purinergic P2 Receptor Antagonists,
pubmed-meshheading:19012950-Receptors, Purinergic P2Y12,
pubmed-meshheading:19012950-Ticlopidine
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients.
|
|
pubmed:affiliation |
Division of Cardiology, University of Florida College of Medicine Jacksonville, Jacksonville, FL 32209, USA. dominick.angiolillo@jax.ufl.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
